You are here: Home > News > Latest updates & news > Lignocaine renamed lidocaine
Read time:


hero image

By Ashleigh McMillan

Anaesthetic lignocaine is being renamed as lidocaine in Australia to align with its international name and reduce confusion for overseas medical staff and travellers.

The Therapeutic Goods Administration will instate a number of name changes of ingredients over the next four years.

Optometry Australia’s national clinical policy advisor Simon Hanna says it is important for practitioners to be aware of the change to align with international standards by April 2020. 

‘For endorsed optometrists, the impact of the change will be to ensure that the correct terminology and spelling are used on prescription pads or in their practice management software,’ Mr Hanna said. ‘Making these amendments in practice will ensure professionalism when presenting to pharmacy and consistency in collaboration with other health-care practitioners.’

Ingredients in the following therapeutically endorsed medicines will be subject to name changes:

  • Amethocaine
  • Atropine
  • Cephazolin
  • Cyclosporin
  • Flurbiprofen
  • Lignocaine

Ingredients which have a significant name change will be labelled with both the new and old ingredient name on packaging until April 2023. For example, lignocaine will be subject to duel-labelling as lidocaine (lignocaine). Other changes in spelling which do not affect pronunciation will not be double-labelled on packaging.

A full list of the ingredients affected by name changes can be found on the Department of Health website.

Filed in category: Uncategorised

Acknowledgement of Country

In the spirit of reconciliation Optometry Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.